Navidea Biopharmaceuticals, Inc. (NAVB)
OTCMKTS
· Delayed Price · Currency is USD
0.0007
+0.0001 (16.67%)
May 1, 2025, 4:00 PM EDT
NAVB Revenue
Navidea Biopharmaceuticals had revenue of $610.00 in the twelve months ending September 30, 2023, down -99.47% year-over-year. In the year 2022, Navidea Biopharmaceuticals had annual revenue of $65.65K, down -87.65%.
Revenue (ttm)
610.00
Revenue Growth
-99.47%
P/S Ratio
114.75
Revenue / Employee
46.92
Employees
13
Market Cap
70.00K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 65.65K | -465.86K | -87.65% |
| Dec 31, 2021 | 531.51K | -383.50K | -41.91% |
| Dec 31, 2020 | 915.01K | 257.19K | 39.10% |
| Dec 31, 2019 | 657.83K | -511.53K | -43.74% |
| Dec 31, 2018 | 1.17M | -641.09K | -35.41% |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Navidea Biopharmaceuticals News
- 4 weeks ago - Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets - Business Wire
- 10 months ago - Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 - Business Wire
- 11 months ago - Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024 - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock - Business Wire
- 1 year ago - NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB) - Business Wire
- 1 year ago - Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel - Business Wire